Tags

Type your tag names separated by a space and hit enter

Visceral leishmaniasis: elimination with existing interventions.
Lancet Infect Dis. 2011 Apr; 11(4):322-5.LI

Abstract

The world's burden of infectious diseases can be substantially reduced by more-effective use of existing interventions. Advances in case detection, diagnosis, and treatment strategies have made it possible to consider the elimination of visceral leishmaniasis in the Indian subcontinent. The priority must now be to effectively implement existing interventions at the community level by actively finding cases in endemic villages and treating them with single-dose liposomal amphotericin B at primary-health-care centres. Once the elimination target of one case per 10,000 population has been reached, combination therapies involving miltefosine and paromomycin can be introduced to ensure long-term availability of several drugs for visceral leishmaniasis and to protect against resistance.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Matlashewski G
Special Programme for Research and Training in Tropical Diseases, WHO, Geneva, Switzerland.
Arana B
No affiliation info available
Kroeger A
No affiliation info available
Battacharya S
No affiliation info available
Sundar S
No affiliation info available
Das P
No affiliation info available
Sinha PK
No affiliation info available
Rijal S
No affiliation info available
Mondal D
No affiliation info available
Zilberstein D
No affiliation info available
Alvar J
No affiliation info available

MeSH

Amphotericin BAntiprotozoal AgentsCommunicable Disease ControlDrug Therapy, CombinationHumansLeishmaniasis, VisceralParomomycinPhosphorylcholine

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21453873

Citation

Matlashewski, Greg, et al. "Visceral Leishmaniasis: Elimination With Existing Interventions." The Lancet. Infectious Diseases, vol. 11, no. 4, 2011, pp. 322-5.
Matlashewski G, Arana B, Kroeger A, et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis. 2011;11(4):322-5.
Matlashewski, G., Arana, B., Kroeger, A., Battacharya, S., Sundar, S., Das, P., Sinha, P. K., Rijal, S., Mondal, D., Zilberstein, D., & Alvar, J. (2011). Visceral leishmaniasis: elimination with existing interventions. The Lancet. Infectious Diseases, 11(4), 322-5. https://doi.org/10.1016/S1473-3099(10)70320-0
Matlashewski G, et al. Visceral Leishmaniasis: Elimination With Existing Interventions. Lancet Infect Dis. 2011;11(4):322-5. PubMed PMID: 21453873.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Visceral leishmaniasis: elimination with existing interventions. AU - Matlashewski,Greg, AU - Arana,Byron, AU - Kroeger,Axel, AU - Battacharya,Sujit, AU - Sundar,Shyam, AU - Das,Pradeep, AU - Sinha,Prabhat Kumar, AU - Rijal,Suman, AU - Mondal,Dinesh, AU - Zilberstein,Dan, AU - Alvar,Jorge, PY - 2011/4/2/entrez PY - 2011/4/2/pubmed PY - 2011/6/1/medline SP - 322 EP - 5 JF - The Lancet. Infectious diseases JO - Lancet Infect Dis VL - 11 IS - 4 N2 - The world's burden of infectious diseases can be substantially reduced by more-effective use of existing interventions. Advances in case detection, diagnosis, and treatment strategies have made it possible to consider the elimination of visceral leishmaniasis in the Indian subcontinent. The priority must now be to effectively implement existing interventions at the community level by actively finding cases in endemic villages and treating them with single-dose liposomal amphotericin B at primary-health-care centres. Once the elimination target of one case per 10,000 population has been reached, combination therapies involving miltefosine and paromomycin can be introduced to ensure long-term availability of several drugs for visceral leishmaniasis and to protect against resistance. SN - 1474-4457 UR - https://www.unboundmedicine.com/medline/citation/21453873/Visceral_leishmaniasis:_elimination_with_existing_interventions_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1473-3099(10)70320-0 DB - PRIME DP - Unbound Medicine ER -